AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00528372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks
Study NCT00528372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin placebo
Description: Tablets, oral, 0 mg, once daily in the morning or evening for up to 102 weeks
Study NCT00528372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT03484403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar back brace
Description: A brace that supports the lumbar region of the spine.
Study NCT03484403 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Back school
Description: Back school consists of patient education physical therapy exercise instruction.
Study NCT03484403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back school
Description: Back school consists of patient education physical therapy exercise instruction.
Study NCT05047614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: including sham
Description: Repositiong feedback training and biofeedback pressure training unit
Study NCT03275389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-SUIV cH8/1N1+AS03
Description: 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 03 (AS03) was administered intramuscularly (IM) in the deltoid region of non-dominant arm.
Study NCT03275389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-SUIV cH5/1N1+AS03
Description: 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
Study NCT03275389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-SUIV cH11/1N1+AS03
Description: 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 03 (AS03) was administered IM in the deltoid region of non-dominant arm.
Study NCT03275389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-SUIV cH8/1N1+AS01
Description: 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
Study NCT03275389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-SUIV cH5/1N1+AS01
Description: 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
Study NCT03275389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-SUIV cH11/1N1+AS01
Description: 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 with Adjuvant System 01 (AS01) was administered IM in the deltoid region of non-dominant arm.
Study NCT03275389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-SUIV cH8/1N1
Description: 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
Study NCT03275389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-SUIV cH5/1N1
Description: 1 Primary dose or 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
Study NCT03275389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-SUIV cH11/1N1
Description: 1 Booster dose of Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1 without adjuvant was administered IM in the deltoid region of non-dominant arm.
Study NCT03275389 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
Study NCT03275389 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1 dose of Phosphate Buffered Saline (PBS) was administered IM in the deltoid region of non-dominant arm.
Study NCT03275389 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix Quadrivalent
Description: 1 Primary dose and 1 Booster dose was administered IM in the deltoid region of non-dominant arm.
Study NCT01162720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long duration tourniquet
Description: Patients randomised to this arm will have the tourniquet applied at the commencement of surgery and removed prior to wound closure.
Study NCT02872311 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Influenza vaccine
Description: Licensed and FDA approved Fluzone HD vaccine to be administered to study participants
Study NCT02872311 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted Influenza vaccine
Description: Licensed and FDA approved FluAd vaccine to be administered to study participants
Study NCT02872311 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Influenza vaccine
Description: Licensed and FDA approved Fluvirin vaccine to be administered to study participants
Study NCT02872311 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Influenza vaccine
Description: Licensed and FDA approved FluBlok vaccine to be administered to study participants
Study NCT00156923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 380 mg
Description: Administered via intramuscular (IM) injection once every 4 weeks for up to 3.5 years.
Study NCT00156923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medisorb naltrexone 190 mg
Description: Administered via IM injection once every 4 weeks for up to 3.5 years.
Study NCT00751634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gaymar Rapr-Round (external cooling blanket)
Description: Application of the device per its approved labeling
Study NCT01253447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor MK2206
Description: 200 mg orally (PO) once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Study NCT01253447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02449083 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: MRI
Study NCT02449083 — intervention group
Intervention type: PROCEDURE
Intervention: coronary angiography
Description: coronary angiography
Study NCT02283021 — intervention group
Intervention type: OTHER
Intervention: A biopsy sample
Description: Sample tissue will be obtained from the routine biopsy taken for pathological evaluation. A pathologist will determine which part of the tissue will be forwarded for this study, to avoid any interference with the pathological evaluation.
Study NCT02089438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Saxagliptin (5 mg) is given before breakfast
Study NCT02089438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin (50mg) is given before breakfast and dinner
Study NCT02089438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin (100 mg) is given before breakfast
Study NCT03770052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duvie
Description: take the intervention drug once daily according to the randomized groups
Study NCT03770052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duvie
Description: take the intervention drug once daily according to the randomized groups
Study NCT02878759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wristbot
Description: The proposed technology comprises a hardware device with four motors that can apply torques to the human wrist about its three degrees of freedom (i.e. axes of rotation: wrist flexion/extension,abduction/adduction and forearm pronation/supination). This allows for guided and controlled movements of the wrist by delivering assistive, resistive, perturbation or no forces (patient actively moves the wrist). It contains a set of specialized software modules that a) allow for the objective, psychophysical assessment of sensory dysfunction in patients, and b) provide specialized training modules designed to improve sensory and motor functions of the wrist.
Study NCT04035330 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: etidronate in sodium hypochlorite
Description: using etidronate in sodium hypochlorite solution with a volume of 5 ml between each instrument to reach a total volume of 25 ml
Study NCT04035330 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: sodium hypochlorite
Description: irrigation with 25 ml 2.5% sodium hypochlorite . 5ml between each instrument.
Study NCT02415283 — intervention group
Intervention type: DEVICE
Intervention: ¹³C-Octanoate Breath Test
Description: Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
Study NCT04356625 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MEPic
Description: * patient in the supine position sitting 45° to 60°,~* closed suction catheter was removed~* a 90° elbow was placed and a bacterial filter in series with endotracheal tube~* adapter was also coupled to the aneroid pressure gauge~* in series an inspiratory unidirectional valve was placed that did not allow expiration~* 2 ml of physiological solution was slowly instilled through the port in the 90º elbow to cause induced cough
Study NCT02615678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture twice a week for 6 weeks then one treatment a week for 4 weeks. Total 16 treatments in 10 weeks.
Study NCT02261298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-4538
Study NCT00746109 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wound packing
Description: 1/4 non-iodoform packing loosely placed inside abscess cavity.
Study NCT00746109 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: NoPacking
Description: This is a routine incision and drainage procedure but without the use of packing. Sterile gauze dressing will be placed over the abscess cavity.
Study NCT01993849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetylcysteine (NAC)
Description: This is the medication N-acetylcysteine (NAC)
Study NCT01993849 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, designed to match in appearance to NAC
Study NCT01659671 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uvulopalatopharyngoplasty
Description: Uvulopalatopharyngoplasty: Resection of the soft palate 3 mm and tonsillectomy, amputation of the uvula to approx 1 cm, single sutures of the posterior pillar to the anterior pillar and of the soft palate.
Study NCT04560062 — intervention group
Intervention type: OTHER
Intervention: Spontaneous changes in diabetes-related health care
Description: The findings of a retrospective cohort analysis conducted in the initial phase of the study will be used in focus groups to identify observed weaknesses in local health systems and will promote possible solutions to strengthen diabetes-related health care. Every focus group will include community members, healthcare workers, decision-makers and diabetic patients and family members.
Study NCT00945399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CARTIPATCH® procedure
Description: Cartilage is harvested and treated for chondrocytes isolation and culture. After multiplication, the chondrocytes are transferred into a biomaterial support and surgically implanted.
Study NCT00945399 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Tiny fractures are created at the cartilage surface to stimulate cartilage growth.
Study NCT02447718 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar®13
Description: A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
Study NCT02447718 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax® 23
Description: A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13
Study NCT02447718 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediacel®
Description: A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
Study NCT02100683 — intervention group
Intervention type: DEVICE
Intervention: PDA Coil
Description: The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter \< 4 mm.
Study NCT02830828 — intervention group
Intervention type: OTHER
Intervention: Investigation of precision pinch grip control
Study NCT01711346 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: S303 Red Blood Cells (RBCs)
Description: Each subject will receive one intravenous infusion of autologous radiolabeled S303 Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
Study NCT01711346 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S303 Red Blood Cells (RBCs)
Description: Each subject will receive one intravenous infusion of autologous radiolabeled S303 Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
Study NCT01711346 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional, untreated Red Blood Cells (RBCs)
Description: Each subject will receive one intravenous infusion of autologous radiolabeled Conventional, untreated Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
Study NCT01711346 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conventional, untreated Red Blood Cells (RBCs)
Description: Each subject will receive one intravenous infusion of autologous radiolabeled Conventional, untreated Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
Study NCT01792843 — intervention group
Intervention type: BEHAVIORAL
Intervention: data
Description: * comparisons of clinical characteristics~* comparisons of cognitive profiles~* comparisons of grey matter density patterns~* comparisons of EEG rhythms features
Study NCT00749359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paxil CR
Description: Paxil CR 37mg tablet manufactures at two different sites
Study NCT04040998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compensatory Cognitive Training
Description: Teach the participants compensatory cognitive skills and strategies
Study NCT03108976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral assessments
Description: Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
Study NCT03108976 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Behavioral assessments
Description: Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
Study NCT03108976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetoencephalography (MEG)
Description: Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
Study NCT03108976 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Magnetoencephalography (MEG)
Description: Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
Study NCT03108976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
Study NCT03108976 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
Study NCT01073319 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo pill
Study NCT01073319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Description: Participants will be randomized to rivastigmine (1.5 mg bid) for 6 days of each phase.
Study NCT01073319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Description: Participants will be randomized to rivastigmine (3 mg bid) for 6 days of each phase.
Study NCT03781245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: All the Right Moves for Subcontractors
Description: All the Right Moves for Subcontractors aims to improve safety, health and wellbeing, through the development of a communication infrastructure with supplemental tools where construction workers and company mangers work together to collaboratively identify problems and strategies to improve their conditions of work. The intervention is grounded in the key characteristics of integrated organizational interventions to improve workers' health safety and wellbeing detailed in Harvard Center for Work, Health and Wellbeing's Implementation Guidelines (McLellan et al, 2016).~The intervention involves a cyclical approach through which the research team facilitate a participatory process to identify workers' health concerns, prioritize these concerns, use an action planning process to identify and operationalize solutions, and develop a company-specific evaluation plan to measure change.
Study NCT03781245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All the Right Moves for Subcontractors
Description: All the Right Moves for Subcontractors aims to improve safety, health and wellbeing, through the development of a communication infrastructure with supplemental tools where construction workers and company mangers work together to collaboratively identify problems and strategies to improve their conditions of work. The intervention is grounded in the key characteristics of integrated organizational interventions to improve workers' health safety and wellbeing detailed in Harvard Center for Work, Health and Wellbeing's Implementation Guidelines (McLellan et al, 2016).~The intervention involves a cyclical approach through which the research team facilitate a participatory process to identify workers' health concerns, prioritize these concerns, use an action planning process to identify and operationalize solutions, and develop a company-specific evaluation plan to measure change.
Study NCT01682798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo yoghurt
Description: 100g of placebo yoghurt will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
Study NCT01682798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yili Chang Qing Pro-ABB yoghurt (Formula 1)
Description: 100g of Yili Chang Qing Pro-ABB yoghurt will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day.
Study NCT01682798 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yili Chang Qing Pro-ABB yoghurt (Formula 2)